Lead party: Charles River Laboratories International, Inc. (lead investor/buyer)
Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).
Target: Noveprim Limited (private company) · Sector: Industrials, Research & Consulting Services · Countries of operation: Mauritius
Transaction type: Investment · Asset class: Corporate Transactions · Strategy: Strategic Minority · Instrument: Equity · Deal amount: US$95m · Equity stake: 0.49% · Implied EV: US$193.9m
Lead investor/buyer: Charles River Laboratories International, Inc. · Investors/buyers: Charles River Laboratories International, Inc.
Legal advisers: not identified in the source record.
Source: announced 31 December 2022. Original announcement: ir.criver.com.


